Effects and safety of 131I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: Results from a multicenter observational registry
スポンサーリンク
概要
- 論文の詳細を見る
Effective treatments for malignant neuroendocrine tumors are under development. While iodine-131 metaiodobenzylguanidine (131I-MIBG) radiotherapy has been used in the treatment of malignant neuroendocrine tumors, there are few studies evaluating its therapeutic effects and safety in a multicenter cohort. In the current study, we sought to evaluate the effects and safety of 131I-MIBG therapy for conditions including malignant pheochromocytoma and paraganglioma within a multicenter cohort. Forty-eight malignant neuroendocrine tumors (37 pheochromocytoma and 11 paraganglioma) from four centers underwent clinical 131I-MIBG radiotherapy. The tumor responses were observed before and 3 to 6 months after the 131I-MIBG radiotherapy in accordance with RECIST criteria. We also evaluated the data for any adverse effects. The four centers performed a total of 87 131I-MIBG treatments on 48 patients between January 2000 and March 2009. Of the treatments, 65 were evaluable using RECIST criteria. One partial response (PR), 40 stable disease (SD), and 9 progressive disease (PD) in malignant pheochromocytoma were observed after each treatment. Fourteen SD and one PD were observed in paraganglioma. Patients with normal hypertension (systolic blood pressure (BP) > 130 mmHg) showed significantly reduced systolic BP after the initial follow-up (n=10, 138.1±8.2 to 129.5±13.5 mmHg, P=0.03). In adult neuroendocrine tumors with a treatment-basis analysis, there were side effects following 41 treatments (47.1%) and most of them (90.2%) were minor. In this multicenter registry, PR or SD was achieved in 84.6% of the treatment occasions in adult neuroendocrine tumors through 131I-MIBG radiotherapy. This indicated that most of the 131I-MIBG radiotherapy was performed safely without significant side effects.
- 一般社団法人 日本内分泌学会の論文
著者
-
FUKUOKA Makoto
Department of Biotracer Medicine, Kanazawa University Graduate School of Medical Sciences
-
Kayano Daiki
Department Of Nuclear Medicine Kanazawa University Hospital
-
SHIGA Tohru
Department of Molecular Imaging, Hokkaido University Graduate School of Medicine
-
Kinuya Seigo
Department Of Biotracer Medicine Kanazawa University Graduate School Of Medical Sciences
-
Yoshinaga Keiichiro
Department Of Cardiology Kagoshima City Medical Association Hospital
-
Higuchi Tetsuya
Department Of Dermatology Tokyo Medical And Dental University School Of Medicine
-
Jinguji Megumi
Department Of Radiology Kagoshima University Graduate School Of Medical And Dental Sciences
-
Okamoto Shozo
Department Of Nuclear Medicine Hokkaido University Graduate School Of Medicine
-
Nakajo Masayuki
Department Of Neuropsychiatry And Radiology Faculty Of Medicine Kagoshima University
-
Ito Yoichi
Department Of Artificial Complex Systems Engineering Hiroshima University
-
Oriuchi Noboru
Department Of Diagnostic Medicine And Nuclear Medicine Gunma University Graduate School Of Medicine
-
Inaki Anri
Department Of Biotracer Medicine Kanazawa University Graduate School Of Medical Sciences
-
Wakabayashi Hiroshi
Department Of Biotracer Medicine Kanazawa University Graduate School Of Medical Sciences
-
Nakajo Masatoyo
Department Of Radiology Graduate School Of Medical And Dental Sciences Kagoshima University
-
Tomiyama Yuuki
Department of Nuclear Medicine, Hokkaido University Graduate School of Medicine
-
Toratani Ayane
Department of Biotracer Medicine, Kanazawa University Graduate School of Medicine, Kanazawa, Japan
-
Nakajo Masayuki
Department of Radiology, Kagoshima University, Graduate School of Medicine, Kagoshima, Japan
関連論文
- Attenuation correction of myocardial SPECT by scatter-photopeak window method in normal subjects
- ^Tc-sestamibi to monitor treatment with antisense oligodeoxynucleotide complementary to MRP mRNA in human breast cancer cells
- Asialoglycoprotein receptor concentration in tumor-bearing livers and its fate early after their sectorial resection
- Intraperitoneal radioimmunotherapy in treating peritoneal carcinomatosis of colon cancer in mice compared with systemic radioimmunotherapy
- Experimental radioimmunotherapy with ^186 Re-MAG3-A7 anti-colorectal cancer monoclonal antibody : Comparison with ^131 I-counterpart
- Enhanced Efficacy of Radioimmunotherapy Combined with Systemic Chemotherapy and Local Hyperthermia in Xenograft Model
- Rhenium-186-mercaptoacetyltriglycine-labeled Monoclonal Antibody for Radioimmunotherapy : In vitro Assessment, in vivo Kinetics and Dosimetry in Tumor-bearing Nude Mice
- Esophageal transit scintigraphy and structured questionnaire in patients with systemic sclerosis with endoscopically proven reflux esophagitis
- Fluctuation of adenosine concentration by modes of intravenous infusion based on mathematical simulation and experiments
- Characterization of cartilaginous tumors with ^Tl scintigraphy